CPRX News and Press, Catalyst Pharmaceuticals Inc. From 02/22/23

Spotlight On Raising Awareness for Rare Diseases on February 28, 2023 Celebrating the Tireless Contributions of Patients and Advocates who Work with the Biotech Industry to Bring New Treatments to the Community CORAL GABLES, Fla., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmac...

Catalyst Pharmaceuticals ( NASDAQ: CPRX ) provided preliminary Q4 and FY reports, expects FY revenue to be $214M, representing 52% Y/Y growth. Expects Q4 total revenues to be ~$61M, ~61% Y/Y growth. Forecasts 2023 total revenues of between $375M-385M, representing 75-80% ...

2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth Forecast 2023 Total Revenues of Between $375 Million and $385 Million Including FYCOMPA ® , Representing YoY Growth of 75% - 80% 2023 FIRDAPSE ® Net Revenues Estimate...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The search for  growth stocks , or companies with high potential for future growth, is on. These growth stocks often represent young, rapidly-expanding companies that are reinvesting their earnings back into their core bu...

Summary Catalyst's rights acquisition of FYCOMPA is a significant step towards controlling the epilepsy treatment market share. The company's cash balance of $256 million is enough to fund its CapEx in 2023. Teva's notice seeking to manufacture a generic version of FIRDAPSE poses a ...

Summary Catalyst has successfully commercialised Firdapse, a therapy for LEMS, earning >$200m from the drug in 2022 likely with a strong profit margin. In 2020/2021, Catalyst was able to overturn an FDA ruling granting Jacobus' rival LEMS drug Ruzurgi approval and access to the same ...

Summary Catalyst Pharmaceuticals, Inc. has been hit with an ANDA notice from Teva Pharmaceutical Industries Limited. Firdapse, at the heart of the ANDA, has had problems before. Catalyst Pharmaceuticals, Inc. is, however, set for cash. Catalyst Pharmaceuticals, Inc. ( CP...

Shareholders of Catalyst Pharmaceuticals (NASDAQ: CPRX) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries (NYSE: TEVA) , was planning to make a generic version of its only marketed drug, Firdapse. With Catalyst's shares fallin...

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023 CORAL GABLES, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catal...

Announced Earlier Today -Notice Received from ANDA Filer for FIRDAPSE® CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercia...